Dimed Distribuidora de Medicamentos (BSP:PNVL3) Research & Development: R$0 Mil (TTM As of Mar. 2026)


BSP:PNVL3 Dimed SA Distribuidora de Medicamentos BSP:PNVL3
89 GF Score
Price R$11.30
GF Value R$13.62
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Dimed Distribuidora de Medicamentos Research & Development?

Dimed Distribuidora de Medicamentos BSP:PNVL3 +4.24% 89 Research & Development is R$0 Mil as of Mar. 2026. GuruFocus rates BSP:PNVL3 with a GF Score™ of 89/100 and a GF Value™ of R$13.62 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dimed Distribuidora de Medicamentos's Research & Development for the three months ended in Mar. 2026 was R$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was R$0 Mil.

Dimed Distribuidora de Medicamentos  (BSP:PNVL3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dimed Distribuidora de Medicamentos Research & Development Related Terms

Dimed Distribuidora de Medicamentos Research & Development Historical Data

* Premium members only.

The historical data trend for Dimed Distribuidora de Medicamentos's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimed Distribuidora de Medicamentos Research & Development Chart

Dimed Distribuidora de Medicamentos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Dimed Distribuidora de Medicamentos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:PNVL3
89GF Score
Dimed SA Distribuidora de Medicamentos BSP:PNVL3
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimed Distribuidora de Medicamentos Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R$0 Mil mean?
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a Research & Development of R$0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Dimed Distribuidora de Medicamentos and its competitors.
Is Dimed Distribuidora de Medicamentos' Research & Development too high?
Dimed Distribuidora de Medicamentos' current Research & Development is R$0 Mil. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' Research & Development compare to LLY and JNJ?
Dimed Distribuidora de Medicamentos' Research & Development of R$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dimed Distribuidora de Medicamentos and its competitors. Dimed Distribuidora de Medicamentos's current Research & Development is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.62, compared to a current price of R$11.30 — trading 17% below its estimated fair value. The current Research & Development is R$0 Mil. Dimed Distribuidora de Medicamentos' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current Research & Development is R$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?

Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued. The current stock price of R$11.30 is trading 17% below its estimated GF Value™ of R$13.62. GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.

Key valuation signals for BSP:PNVL3:

  • Research & Development: R$0 Mil
  • GF Value™: R$13.62 vs. price of R$11.30 (17% below fair value)
  • GF Score™: 89/100 with 5 warning signs

No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dimed Distribuidora de Medicamentos Business Description

Address Avenida Industrial Belgraf, 865, Eldorado do Sul, RS, BRA, 92990-000
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
89GF Score

Get the complete analysis for BSP:PNVL3

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$11.30
Price
R$13.62
GF Value